報價延遲最少15分鐘:2025/03/28 08:23 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.27 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.53/-1.00
|
|
企業價值
33.06M
|
| 資產負債 |
|
每股賬面淨值
3.80
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
196.00K
|
|
每股收益
0.01
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/03/28 08:23 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage. |